Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biogen and UPenn join forces to commercialize gene therapies

Nature Biotechnology volume 34, pages 791–793 (2016)Cite this article

Subjects

The alliance, which will use adeno-associated virus (AAV) vectors to target diseases of the central nervous system as well as conditions affecting skeletal muscle and the eye, has a personal dimension. Back in the 1980s, Olivier Danos, now the Biogen executive responsible for steering the company's gene therapy strategy, and James Wilson, director of the Gene Therapy Program at UPenn's Perelman School of Medicine, in Philadelphia, shared a bench as postdocs in the laboratory of Richard Mulligan at the Whitehead Institute at the Massachusetts Institute of Technology; Mulligan is now a member of Biogen's board and chairs its science and technology committee.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Biogen and UPenn join forces to commercialize gene therapies. Nat Biotechnol 34, 791–793 (2016). https://doi.org/10.1038/nbt0816-791

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0816-791

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research